• M A Trad, W Naughton, A Yeung, L Mazlin, M O'sullivan, N Gilroy, D A Fisher, and R L Stuart.
• Department of Infectious Diseases, Wollongong Hospital, Wollongong, NSW, Australia; Graduate School of Medicine, University of Wollongong, Wollongong, Australia; Medecins Sans Frontieres, Paris, France. Electronic address: m.a.trad@hotmail.com.
• J. Clin. Virol. 2017 Jan 1; 86: 5-13.

AbstractEbola virus disease (EVD) is characterised by systemic viral replication, immuno-suppression, abnormal inflammatory responses, large volume fluid and electrolyte losses, and high mortality in under-resourced settings. There are various therapeutic strategies targeting EVD including vaccines utilizing different antigen delivery methods, antibody-based therapies and antiviral drugs. These therapies remain experimental, but received attention following their use particularly in cases treated outside West Africa during the 2014-15 outbreak, in which 20 (80%) out of 25 patients survived. Emerging data from current trials look promising and are undergoing further study, however optimised supportive care remains the key to reducing mortality from EVD.Crown Copyright © 2016. Published by Elsevier B.V. All rights reserved.

13 keywords...

hide…